BioNTech’s €16.8 Billion Reserve Can’t Mask the Pain of Its Oncology Pivot as ASCO Data Nears

BioNTech posts €531.9M Q1 loss as oncology R&D costs soar. Shares down 12%. Board adds oncology experts; pumitamig data at ASCO May 29.

BioNTech’s transformation from pandemic-era vaccine champion to oncology contender is proving expensive — and investors are watching the meter tick. The Mainz-based biotech posted a net loss of €531.9 million in the first quarter, as research and development spending surged past $650 million (roughly €600 million). Revenue from the COVID-19 vaccine franchise, now seasonal and shrinking, came in at €118.1 million, underscoring how far the company has moved from its former cash cow.

The stock reflects the market’s caution. At around €76, the shares have shed more than 12% over the past month and trade about 12% below their 200-day moving average. The 52-week high of €101.90, set last summer, looks distant. The market is pricing in execution risk for a pipeline that has yet to deliver a commercial cancer product.

To bridge that gap, BioNTech is strengthening its governance. At the annual general meeting — which represented 92% of total share capital — shareholders approved expanding the supervisory board from six to eight seats. The new members are Prof. Iris Löw-Friedrich, whose background spans medical innovation and commercial launch expertise, and Susanne Schaffert, a seasoned oncology specialist already serving on the board of Merck KGaA. Existing supervisors Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were re-elected, with Jeggle staying on as chairman.

The board revamp is no cosmetic exercise. As BioNTech’s late-stage oncology candidates near potential market entries, the company needs experience in pricing, reimbursement, and sales — areas where the new appointees add direct value. The timing aligns with a pipeline that is rapidly maturing. BioNTech now runs more than 25 clinical studies in mid-to-late stages, spanning 17 programs. Management expects to have 15 Phase 3 trials underway by the end of 2026, with seven late-stage data readouts due this year alone.

The most immediate catalyst is pumitamig, a bispecific immune modulator. For this candidate alone, five additional registrational studies were initiated in 2026, targeting indications including gastric cancer and non-small cell lung cancer. A pivotal moment comes on May 29 at the ASCO congress, where BioNTech will unveil Phase 2 data from the ROSETTA-Lung-02 trial. There, pumitamig will be compared head-to-head against pembrolizumab (Keytruda), the current standard of care in lung cancer immunotherapy. A strong showing could fundamentally reshape how analysts view the pipeline’s commercial potential.

Financially, BioNTech is well-armed. The company held €16.8 billion in cash, cash equivalents, and securities at the end of March, giving it ample runway for expensive late-stage development. It also has an active American depositary share buyback program of up to $1 billion, running through May 6, 2027, primarily intended to offset share-based compensation. In a further move that raised some eyebrows, shareholders authorized a capital increase of up to 50% of existing share capital. Management framed it not as an emergency measure but as strategic firepower for potential acquisitions or partnerships — a signal that the company is open to using its balance sheet to accelerate the oncology push.

For the full year 2026, management maintains its revenue guidance of €2.0 billion to €2.3 billion, a range largely supported by the remaining vaccine business. Until the oncology pipeline delivers, BioNTech remains a story of high investment, deep losses, and a stock waiting for a data-driven inflection point. The ASCO presentation later this month could be the moment that begins to change the narrative — or confirms the market’s skepticism.